Literature DB >> 19091401

The role of phagosomal pH on the size-dependent efficiency of cross-presentation by dendritic cells.

Kenny K Tran1, Hong Shen.   

Abstract

Vaccines able to stimulate CD8(+) T cells are crucial in controlling a broad range of infectious diseases and tumors. To induce effective CD8(+) T cell responses, exogenous antigen has to be cross-presented onto major histocompatibility complex (MHC) class I molecules by dendritic cells. Although particle size has been recognized as a critical factor of vaccine design, it is unclear how the size of vaccine carriers impacts the intracellular processing of exogenous antigen and cross-presentation onto MHC class I molecules. In this study, by using polystyrene beads with narrowly defined sizes as model antigen carriers, we demonstrate that particle size mediates the efficiency of cross-presentation of exogenous antigens. By examining the intracellular trafficking, kinetics of phagosomal pH and degradation of antigens bounded to beads, we illustrate the possible mechanisms attributed to the profound effect of particle size on the efficiency of cross-presentation. Antigen bounded to 50 nm beads was shuttled rapidly to an acidic environment within half an hour post-exposure to cells, leading to its rapid and unregulated degradation and inefficient cross-presentation. In contrast, antigen bounded to 500 nm and 3 microm beads remained in a more neutral environment, which preserved the majority of antigens, leaving it available for the generation of peptides to be loaded onto MHC class I molecules. We conclude that the size of antigen carriers plays a critical role in directing antigen to the class I antigen presentation pathway. Our results, together with previous in vivo studies on the effect of particle size on CD8(+) T cell responses, provide insight into the rational design of vaccines for the stimulation of cell-mediated immunity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19091401      PMCID: PMC2735406          DOI: 10.1016/j.biomaterials.2008.11.034

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  36 in total

Review 1.  Cross-presentation in viral immunity and self-tolerance.

Authors:  W R Heath; F R Carbone
Journal:  Nat Rev Immunol       Date:  2001-11       Impact factor: 53.106

2.  ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells.

Authors:  Pierre Guermonprez; Loredana Saveanu; Monique Kleijmeer; Jean Davoust; Peter Van Endert; Sebastian Amigorena
Journal:  Nature       Date:  2003-09-25       Impact factor: 49.962

3.  Phagosomes are competent organelles for antigen cross-presentation.

Authors:  Mathieu Houde; Sylvie Bertholet; Etienne Gagnon; Sylvain Brunet; Guillaume Goyette; Annie Laplante; Michael F Princiotta; Pierre Thibault; David Sacks; Michel Desjardins
Journal:  Nature       Date:  2003-09-25       Impact factor: 49.962

4.  Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors.

Authors:  Theodora Fifis; Anita Gamvrellis; Blessing Crimeen-Irwin; Geoffrey A Pietersz; Jie Li; Patricia L Mottram; Ian F C McKenzie; Magdalena Plebanski
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

Review 5.  Phagocytosis: at the crossroads of innate and adaptive immunity.

Authors:  Isabelle Jutras; Michel Desjardins
Journal:  Annu Rev Cell Dev Biol       Date:  2005       Impact factor: 13.827

6.  Quantitative and dynamic assessment of the contribution of the ER to phagosome formation.

Authors:  Nicolas Touret; Paul Paroutis; Mauricio Terebiznik; Rene E Harrison; Sergio Trombetta; Marc Pypaert; Amy Chow; Aimin Jiang; James Shaw; Christopher Yip; Hsiao-Ping Moore; Nicole van der Wel; Diane Houben; Peter J Peters; Chantal de Chastellier; Ira Mellman; Sergio Grinstein
Journal:  Cell       Date:  2005-10-07       Impact factor: 41.582

Review 7.  Mechanisms of MHC class I-restricted antigen processing and cross-presentation.

Authors:  Peter Cresswell; Anne L Ackerman; Alessandra Giodini; David R Peaper; Pamela A Wearsch
Journal:  Immunol Rev       Date:  2005-10       Impact factor: 12.988

8.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines.

Authors:  Sai T Reddy; André J van der Vlies; Eleonora Simeoni; Veronique Angeli; Gwendalyn J Randolph; Conlin P O'Neil; Leslie K Lee; Melody A Swartz; Jeffrey A Hubbell
Journal:  Nat Biotechnol       Date:  2007-09-16       Impact factor: 54.908

9.  The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent.

Authors:  M P Desai; V Labhasetwar; E Walter; R J Levy; G L Amidon
Journal:  Pharm Res       Date:  1997-11       Impact factor: 4.200

10.  Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages.

Authors:  M Kovacsovics-Bankowski; K Clark; B Benacerraf; K L Rock
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

View more
  32 in total

Review 1.  Conscripts of the infinite armada: systemic cancer therapy using nanomaterials.

Authors:  David A Scheinberg; Carlos H Villa; Freddy E Escorcia; Michael R McDevitt
Journal:  Nat Rev Clin Oncol       Date:  2010-03-30       Impact factor: 66.675

2.  Specific T cell induction using iron oxide based nanoparticles as subunit vaccine adjuvant.

Authors:  Lázaro Moreira Marques Neto; Nicholas Zufelato; Ailton Antônio de Sousa-Júnior; Monalisa Martins Trentini; Adeliane Castro da Costa; Andris Figueiroa Bakuzis; André Kipnis; Ana Paula Junqueira-Kipnis
Journal:  Hum Vaccin Immunother       Date:  2018-07-12       Impact factor: 3.452

Review 3.  Designing CD8+ T cell vaccines: it's not rocket science (yet).

Authors:  Jonathan W Yewdell
Journal:  Curr Opin Immunol       Date:  2010-05-04       Impact factor: 7.486

Review 4.  Biomaterials for nanoparticle vaccine delivery systems.

Authors:  Preety Sahdev; Lukasz J Ochyl; James J Moon
Journal:  Pharm Res       Date:  2014-05-22       Impact factor: 4.200

Review 5.  Advancing drug delivery systems for the treatment of multiple sclerosis.

Authors:  Inna Tabansky; Mark D Messina; Catherine Bangeranye; Jeffrey Goldstein; Karen M Blitz-Shabbir; Suly Machado; Venkatesh Jeganathan; Paul Wright; Souhel Najjar; Yonghao Cao; Warren Sands; Derin B Keskin; Joel N H Stern
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

6.  Effects of particle size on toll-like receptor 9-mediated cytokine profiles.

Authors:  Helen C Chen; Bingbing Sun; Kenny K Tran; Hong Shen
Journal:  Biomaterials       Date:  2010-12-03       Impact factor: 12.479

7.  Antigen cross-presentation by dendritic cell subsets: one general or all sergeants?

Authors:  Stefan Nierkens; Jurjen Tel; Edith Janssen; Gosse J Adema
Journal:  Trends Immunol       Date:  2013-03-27       Impact factor: 16.687

Review 8.  Dawn of advanced molecular medicine: nanotechnological advancements in cancer imaging and therapy.

Authors:  Charalambos Kaittanis; Travis M Shaffer; Daniel L J Thorek; Jan Grimm
Journal:  Crit Rev Oncog       Date:  2014

9.  Effect of the poly(ethylene glycol) (PEG) density on the access and uptake of particles by antigen-presenting cells (APCs) after subcutaneous administration.

Authors:  Xi Zhan; Kenny K Tran; Hong Shen
Journal:  Mol Pharm       Date:  2012-11-20       Impact factor: 4.939

10.  Enabling customization of non-viral gene delivery systems for individual cell types by surface-induced mineralization.

Authors:  Bingbing Sun; Kenny K Tran; Hong Shen
Journal:  Biomaterials       Date:  2009-08-19       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.